(Q37798093)

23 August 2017

title

Low-molecular-weight heparin overdose: management by observation (English)

1 reference

23 August 2017

1 reference

1 reference

1

Andrew A Monte

1 reference

23 August 2017

Michael Bodmer

2

1 reference

23 August 2017

Tammi H Schaeffer

series ordinal

3

1 reference

23 August 2017

language of work or name

English

0 references

publication date

5 October 2010

1 reference

Annals of Pharmacotherapy

23 August 2017

published in

1 reference

23 August 2017

volume

44

1 reference

23 August 2017

issue

11

1 reference

23 August 2017

page(s)

1836-1839

1 reference

Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)

23 August 2017

cites work

1 reference

Pharmacodynamic and pharmacokinetic properties of enoxaparin : implications for clinical practice

21 January 2018

1 reference

Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

21 January 2018

1 reference

Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors

21 January 2018

1 reference

Mechanisms responsible for the failure of protamine to inactivate low-molecular-weight heparin.

21 January 2018

1 reference

Incomplete reversal of enoxaparin toxicity by protamine: implications of renal insufficiency, obesity, and low molecular weight heparin sulfate content

21 January 2018

1 reference

The pharmacokinetics of subcutaneous enoxaparin in end-stage renal disease

21 January 2018

1 reference

Pharmacokinetics of the low molecular weight heparin enoxaparin during 48 h after bolus administration as an anticoagulant in haemodialysis

21 January 2018

1 reference

Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings

21 January 2018

1 reference

Recombinant activated factor VII effectively reverses the anticoagulant effects of heparin, enoxaparin, fondaparinux, argatroban, and bivalirudin ex vivo as measured using thromboelastography

21 January 2018

1 reference

Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers.

21 January 2018

1 reference

Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers

21 January 2018

1 reference

Recombinant factor VIIa to manage major bleeding from newer parenteral anticoagulants

21 January 2018

1 reference

A [+18RGD] protamine variant for nontoxic and effective reversal of conventional heparin and low-molecular-weight heparin anticoagulation

21 January 2018

1 reference

Prolonged antithrombin activity of low-molecular-weight heparins. Clinical implications for the treatment of thromboembolic diseases.

21 January 2018

1 reference

Serious anaphylactic reactions due to protamine sulfate: a systematic literature review

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1P318

1 reference

23 August 2017

1 reference